Dr. Thomas Hecht, Chairman
Dr. Thomas Hecht, is chairman of Affimed's Supervisory Board since 2007 and Head of HHC consulting in Kuessnacht, Switzerland.
He was previously Vice President Marketing at Amgen Europe, Lucerne, Switzerland.
A seasoned manager and industry professional, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002.
Prior to joining the biopharmaceutical industry, he certified in internal medicine and served as Co-Head of the Program for Bone Marrow Transplantation, University of Freiburg, Germany.
provides services to the pharmaceutical industry in clinical development/ marketing and licensing strategies through HHC
, a biopharmaceutical consulting company founded in 2002.
He also serves as Chairman of the Boards of Cell Medica Ltd., Delenex AG and as Member of the Board of Humabs BioMed AG.
In 2009, with the acquisition by Alcon, he stepped down from the Chairmanship of ESBATech AG; and in 2015, with the acquisition by Baxter International Inc., from his post as Chairman of the Supervisory Council of SuppreMol GmbH.